[ET Net News Agency, 14 April 2021] Morgan Stanley raised its target price for Hansoh
Pharma (03692) to HK$51 from HK$50 and maintained its "overweight" rating.
The research house said it cuts its 2021-2023 earnings estimates by 2-7%, following the
earnings miss in 2H20, mainly due to centralized procurement price cuts on generic drugs.
But, given recent inclusions of three innovative drugs into the national reimbursement
list and multiple global licensing deals, it thinks that business visibility has
significantly improved. Hence, it extends the explicit forecast period by 7 years to end
at 2030. As a result, the price target and scenario values rise by 2-3%. (RC)